311 related articles for article (PubMed ID: 37441498)
1. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Srinonprasert V; Anothaisintawee T; Kongmalai P; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1182037. PubMed ID: 37441498
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
[TBL] [Abstract][Full Text] [Related]
3. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
[TBL] [Abstract][Full Text] [Related]
7. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
Yuan X; Gao Z; Yang C; Duan K; Ren L; Song G
Front Endocrinol (Lausanne); 2023; 14():1170881. PubMed ID: 37342259
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.
Gu Y; Sun L; He Y; Yang L; Deng C; Zhou R; Kong T; Zhang W; Chen Y; Li J; Shi J
Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):273-282. PubMed ID: 36689199
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
Yan H; Huang C; Shen X; Li J; Zhou S; Li W
Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
[TBL] [Abstract][Full Text] [Related]
10. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis.
Guo N; Shi H; Zhang H; Wang H
Eur J Clin Pharmacol; 2023 Nov; 79(11):1465-1474. PubMed ID: 37682287
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Deng M; Wen Y; Yan J; Fan Y; Wang Z; Zhang R; Ren L; Ba Y; Wang H; Lu Q; Fan H
BMC Med; 2023 Nov; 21(1):447. PubMed ID: 37974258
[TBL] [Abstract][Full Text] [Related]
15. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang L; Li J; Zeng H; Liu J
Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
Tran S; Retnakaran R; Zinman B; Kramer CK
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
[TBL] [Abstract][Full Text] [Related]
17. Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.
Li J; Ji C; Zhang W; Lan L; Ge W
J Diabetes Complications; 2023 Jan; 37(1):108362. PubMed ID: 36462459
[TBL] [Abstract][Full Text] [Related]
18. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Carbone LJ; Angus PW; Yeomans ND
J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
[TBL] [Abstract][Full Text] [Related]
20. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
Yang S; He W; Zhao L; Mi Y
PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
